ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Sinovac Biotech Ltd

Sinovac Biotech Ltd (SVA)

6.47
0.00
(0.00%)
Closed 28 December 8:00AM
6.47
0.00
( 0.00% )
Pre Market: 11:00AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
6.47
Bid
6.47
Offer
6.26
Volume
-
0.00 Day's Range 0.00
6.47 52 Week Range 6.47
Market Cap
Previous Close
6.47
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
71,139,402
Dividend Yield
-
PE Ratio
-1.78
Earnings Per Share (EPS)
-3.63
Revenue
448.27M
Net Profit
-258.36M

About Sinovac Biotech Ltd

Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), ... Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Saint John, Atg
Founded
-
Sinovac Biotech Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SVA. The last closing price for Sinovac Biotech was US$6.47. Over the last year, Sinovac Biotech shares have traded in a share price range of US$ 6.47 to US$ 6.47.

Sinovac Biotech currently has 71,139,402 shares in issue. The market capitalisation of Sinovac Biotech is US$460.27 million. Sinovac Biotech has a price to earnings ratio (PE ratio) of -1.78.

SVA Latest News

シノバック、手足口病(HFMD)に対する2価ワクチンの第III相臨床試験を開始

手足口病に対する多価ワクチンの第III相臨床試験は世界で初めての試みとなる (ビジネスワイヤ) -- 中国のバイオ医薬品におけるリーディングプロバイダーであるシノバック・バイオテック( 「シノバック」...

SINOVAC hat eine klinische Phase-III-Studie zu einem bivalenten Impfstoff gegen Hand-Fuß-Mund-Krankheit (HFMD) initiiert

Die weltweit erste klinische Phase-III-Studie zu einem multivalenten HFMD-Impfstoff Sinovac Biotech Ltd. („SINOVAC“ oder das „Unternehmen“) (NASDAQ: SVA), ein führender Anbieter von...

SINOVAC a lancé un essai clinique de Phase III sur un vaccin bivalent contre la maladie mains-pieds-bouche (MMPB)

Le premier essai clinique de Phase III au monde sur un vaccin multivalent contre la MMPB Sinovac Biotech Ltd. (« SINOVAC » ou la « Société ») (NASDAQ : SVA), l'un des principaux fournisseurs de...

SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)

The first phase III clinical trial on a multivalent HFMD vaccine in the world Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in...

SINOVAC Reports Unaudited First Half of 2024 Financial Results

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months...

SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1006.476.476.4700CS
4006.476.476.4700CS
12006.476.476.4700CS
26006.476.476.4700CS
52006.476.476.4700CS
156006.476.476.4700CS
260006.476.476.4700CS

SVA - Frequently Asked Questions (FAQ)

What is the current Sinovac Biotech share price?
The current share price of Sinovac Biotech is US$ 6.47
How many Sinovac Biotech shares are in issue?
Sinovac Biotech has 71,139,402 shares in issue
What is the market cap of Sinovac Biotech?
The market capitalisation of Sinovac Biotech is USD 460.27M
What is the 1 year trading range for Sinovac Biotech share price?
Sinovac Biotech has traded in the range of US$ 6.47 to US$ 6.47 during the past year
What is the PE ratio of Sinovac Biotech?
The price to earnings ratio of Sinovac Biotech is -1.78
What is the cash to sales ratio of Sinovac Biotech?
The cash to sales ratio of Sinovac Biotech is 1.03
What is the reporting currency for Sinovac Biotech?
Sinovac Biotech reports financial results in USD
What is the latest annual turnover for Sinovac Biotech?
The latest annual turnover of Sinovac Biotech is USD 448.27M
What is the latest annual profit for Sinovac Biotech?
The latest annual profit of Sinovac Biotech is USD -258.36M
What is the registered address of Sinovac Biotech?
The registered address for Sinovac Biotech is 36 LONG STREET, SAINT JOHN
What is the Sinovac Biotech website address?
The website address for Sinovac Biotech is www.sinovac.com
Which industry sector does Sinovac Biotech operate in?
Sinovac Biotech operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AALAmerican Airlines Group Inc
US$ 17.34
(0.00%)
276.91k
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 69.73
(0.00%)
0
AADIAadi Bioscience Inc
US$ 3.21
(0.00%)
4.84k
AACGATA Creativity Global
US$ 0.762551
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 17.34
(0.00%)
282.45k
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 69.73
(0.00%)
0
AADIAadi Bioscience Inc
US$ 3.21
(0.00%)
4.84k
AACGATA Creativity Global
US$ 0.762551
(0.00%)
0
NXUNXU Inc
US$ 0.2434
(0.00%)
125.6M
WATTEnergous Corporation
US$ 0.4112
(0.00%)
65.68M
VINCVincerx Inc
US$ 0.194
(0.00%)
28.14M
INTZIntrusion Inc
US$ 2.16
(0.00%)
27.09M
HOLOMicroCloud Hologram Inc
US$ 2.40
(0.00%)
26.76M

SVA Discussion

View Posts
AlternativeLiquidity AlternativeLiquidity 12 months ago
Tender offer for Sinovac Shares:
https://www.sec.gov/Archives/edgar/data/1084201/000187041224000001/0001870412-24-000001-index.htm

Investor Letter:
https://www.sec.gov/Archives/edgar/data/1084201/000187041224000001/Exhibit_A3.htm

For investors that are sick of holding the shares, this might be a good opportunity to exit.

Annual reports and other public disclosures from the company are available here:

https://www.sec.gov/edgar/browse/?CIK=0001084201

👍️0
mick mick 12 months ago
https://www.otcmarkets.com/stock/SVA
👍️0
mick mick 1 year ago
https://www.otcmarkets.com/stock/SVA
👍️0
mick mick 1 year ago
https://www.otcmarkets.com/stock/SVA
👍️0
mick mick 1 year ago
https://www.otcmarkets.com/stock/SVA
👍️0
IHuser IHuser 1 year ago
imo... i guarantee my following will destroy this ticker....quickly...SVA

IHuser
👍️0
IHuser IHuser 1 year ago
imo... ya mick me and my boys own this market now.....gl...wont be a market soon~



IHuser
👍️0
mick mick 1 year ago
https://www.otcmarkets.com/stock/SVA
👍️0
mick mick 1 year ago
SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -
👍️0
mick mick 1 year ago
SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume:
👍️0
mick mick 2 years ago
SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -
👍️0
mick mick 2 years ago
SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -
👍️0
mick mick 2 years ago
Date

Event

January 28, 2020

SINOVAC established and launched a new COVID-19 vaccine research and development project

June 13, 2020

SINOVAC announced a Phase I/II clinical study of its new COVID-19 vaccine, showing the vaccine was safe and effective in producing neutralizing antibodies

February 16, 2021

Professor Lau Chak-sing, Convener of the Hong Kong Vaccine Advisory Expert Committee, announced the committee’s review of data for CoronaVac®. Results showed CoronaVac® benefits outweigh the risks. The committee recommended the vaccine to the government

February 19, 2021

Within 72 hours after the advisory committee's recommendation, the first batch of one million doses of CoronaVac® arrived in Hong Kong from Beijing. Hong Kong subsequently launched a large-scale COVID-19 vaccination program

June 2, 2022

CoronaVac® was validated by the World Health Organization’s Emergency Use List Procedure

February 20, 2022

SINOVAC Foundation donations to Hong Kong helped local communities in the fight against the COVID-19 pandemic

April 14, 2022

In cooperation with HKU and Gleneagles Hospital, SINOVAC’s inactivated COVID-19 vaccine (omicron variant) was approved for clinical trials in Hong Kong

August 4, 2022

Children between the ages of 6 months and 3 years old were eligible for receiving CoronaVac®. To help the public complete their vaccinations as soon as possible, Hong Kong had opened up multiple new vaccination centers.

December 16, 2022

CoronaVac® was fully registered in Hong Kong under the Pharmacy and Poisons Ordinance Cap 138. It is one of the first COVID-19 vaccines approved for official registration in Hong Kong

May 10, 2023

SINOVAC announced the supply of the inactivated COVID-19 vaccine CoronaVac® (original strain) to Hong Kong’s private market, with plans to donate free COVID-19 vaccines to children

[1] HKSAR news.gov.hk: Professor Lo Chung Mo’s Chinese article dated 15 Sept 2022. https://www.news.gov.hk/chi/2022/09/20220915/20220915_145920_647.html

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

For more information, please see the Company’s website at www.sinovac.com.



View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005485/en/

Sinovac Biotech Ltd.
PR Team
pr@sinovac.com
👍️0
mick mick 2 years ago
decrease in sales <> https://www.otcmarkets.com/filing/html?id=16605858&guid=_1T-knRCUJRXB3h
👍️0
mick mick 2 years ago
interesting review <> https://ih.advfn.com/stock-market/NASDAQ/sinovac-biotech-SVA/stock-news/91160230/amended-statement-of-beneficial-ownership-sc-13d-a

$SVA
👍️0
mick mick 2 years ago
Amended Statement of Beneficial Ownership (sc 13d/a) • Edgar (US Regulatory) • 05/25/2023 11:14:28 AM
CoronaVac® von SINOVAC erfüllt Hongkongs Bedarf an COVID-19-Impfstoffen zur Selbstzahlung • Business Wire • 05/12/2023 04:22:00 PM
??????CoronaVac ®????????????COVID-19????????????????? • Business Wire • 05/10/2023 06:02:00 PM
Le vaccin CoronaVac® de SINOVAC répond au besoin pour des vaccins contre la COVID-19 autopayés à Hong Kong • Business Wire • 05/10/2023 06:02:00 PM
👍️0
mick mick 2 years ago
SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume:
👍️0
mick mick 2 years ago
SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume:
👍️0
mick mick 2 years ago
Sinovac ändert Plan für Aktionärsrechte • Business Wire • 02/22/2023 03:20:00 PM
Amended Securities Registration (section 12(b)) (8-a12b/a) • Edgar (US Regulatory) • 02/22/2023 11:31:40 AM
👍️0
mick mick 2 years ago
Recent SVA News
???????????????? • Business Wire • 02/23/2023 12:38:00 PM
Sinovac modifie le régime de droits des actionnaires • Business Wire • 02/22/2023 05:02:00 PM
Sinovac ändert Plan für Aktionärsrechte • Business Wire • 02/22/2023 03:20:00 PM
Amended Securities Registration (section 12(b)) (8-a12b/a) • Edgar (US Regulatory) • 02/22/2023 11:31:40 AM
👍️0
mick mick 2 years ago
SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume:
👍️0
mick mick 2 years ago
SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume:
👍️0
mick mick 2 years ago
$SVA http://www.sinovac.com/
👍️0
mick mick 2 years ago
SINOVAC Reports Unaudited First Half of 2022 Financial ResultsBUSINESS WIRE | 12/29/2022
👍️0
mick mick 2 years ago
FORM TYPE RECEIVED PERIOD END DATE REPORT
6-K 12/29/2022 12/29/2022 PDFRTFHTMLXLS
SC 13D/A 12/12/2022 PDFRTFHTMLXLS
6-K 11/04/2022 11/04/2022 PDFRTFHTML
6-K 06/09/2022 06/09/2022 PDFRTFHTML
6-K 05/06/2022 05/06/2022 PDFRTFHTML
6-K 05/02/2022 04/29/2022 PDFRTFHTMLXLS
20-F 04/29/2022 12/31/2021 PDFRTFHTMLXLS
8-A12B/A 02/22/2022 PDFRTFHTMLXLS
6-K 02/22/2022 02/22/2022 PDFRTFHTML
6-K 12/30/2021 12/30/2021 PDFRTFHTMLXLS
👍️0
mick mick 2 years ago
SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -
👍️0
mick mick 2 years ago
SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -
👍️0
mick mick 2 years ago
SVA Latest News
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 12/29/2022 08:41:47 AM
SINOVAC Reports Unaudited First Half of 2022 Financial Results 12/29/2022 08:30:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) 12/12/2022 06:45:09 AM
?????????????WHO???????? 11/04/2022 08:01:00 AM
👍️0
mick mick 2 years ago
https://www.otcmarkets.com/stock/SVA/security
👍️0
mick mick 2 years ago
SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume:
👍️0
mick mick 2 years ago
https://www.otcmarkets.com/stock/SVA/disclosure
👍️0
mick mick 2 years ago
Recent SVA News
???????????????COVID-19????????????????????? • Business Wire • 09/07/2022 11:57:00 AM
SINOVAC erhält Genehmigung für klinische Studie zu seinem Omikron-COVID-19-Impfstoff in Chile • Business Wire • 09/06/2022 07:20:00 PM
SINOVAC autorisé à lancer au Chili un essai clinique pour son vaccin contre le variant Omicron du Covid-19 • Business Wire • 09/06/2022 02:03:00 PM
👍️0
mick mick 2 years ago
Recent SVA News
???????????????COVID-19????????????????????? • Business Wire • 09/07/2022 11:57:00 AM
SINOVAC erhält Genehmigung für klinische Studie zu seinem Omikron-COVID-19-Impfstoff in Chile • Business Wire • 09/06/2022 07:20:00 PM
SINOVAC autorisé à lancer au Chili un essai clinique pour son vaccin contre le variant Omicron du Covid-19 • Business Wire • 09/06/2022 02:03:00 PM
👍️0
mick mick 2 years ago
SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
👍️0
mick mick 2 years ago
Recent SVA News
???????????????COVID-19????????????????????? • Business Wire • 09/07/2022 11:57:00 AM
SINOVAC erhält Genehmigung für klinische Studie zu seinem Omikron-COVID-19-Impfstoff in Chile • Business Wire • 09/06/2022 07:20:00 PM
SINOVAC autorisé à lancer au Chili un essai clinique pour son vaccin contre le variant Omicron du Covid-19 • Business Wire • 09/06/2022 02:03:00 PM
👍️0
mick mick 2 years ago
https://www.nytimes.com/2020/12/25/health/turkey-brazil-sinovac-coronavirus-vaccine.html?source=content_type%3Areact%7Cfirst_level_url%3Aarticle%7Csection%3Amain_content%7Cbutton%3Abody_link
Turkey signed a deal with Sinovac for 50 million doses of the vaccine. The first three million doses are scheduled to arrive Monday in Turkey,
Mr. Koca said. Mr. Koca said Turkey would also get 4.5 million doses of the Pfizer-BioNTech vaccine by the end of March.
Around 1 million doses are expected to arrive at the end of January, he said.
👍️0
mick mick 2 years ago
Contact: Stella Wang
Email: http://www.Stellawang@1globe-china.com
👍️0
mick mick 2 years ago
Contact: Stella Wang
Email: http://www.Stellawang@1globe-china.com
👍️0
mick mick 2 years ago
http://www.sinovac@sinovac.com
👍️0
mick mick 2 years ago
http://www.pr@sinovac.com
👍️0
mick mick 2 years ago
Recent SVA News
??????COVID-19??????????6????????????????? • Business Wire • 08/05/2022 06:19:00 PM
L'utilisation du vaccin anti-COVID-19 de SINOVAC approuvée à partir de l'âge de six mois à Hong Kong • Business Wire • 08/03/2022 04:45:00 PM
COVID-19-Impfstoff von SINOVAC in Hongkong zur Verwendung bei Kindern ab einem Alter von 6 Monaten zugelassen • Business Wire • 08/03/2022 04:45:00 PM
SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong • Business Wire • 08/03/2022 10:00:00 AM
?????????4???????????????????? • Business Wire • 07/20/2022 12:00:00 PM
SINOVAC startet klinische Studie für seinen Vierfach-Grippeimpfstoff in Chile • Business Wire • 07/19/2022 01:31:00 PM
SINOVAC lance un essai clinique au Chili pour son vaccin antigrippal quadrivalent • Business Wire • 07/19/2022 11:16:00 AM
👍️0
mick mick 2 years ago
SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -
Bid: 6.93
Ask: 6.00
SVA Detailed Quote
👍️0
mick mick 2 years ago
SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -
Bid: 6.93
Ask: 6.10
SVA Detailed Quote
👍️0
mick mick 2 years ago
https://www.otcmarkets.com/stock/SVA/overview
👍️0
mick mick 2 years ago
https://www.otcmarkets.com/stock/SVA/overview
👍️0
mick mick 2 years ago
never answered e-mail $SVA
👍️0
mick mick 2 years ago
yes hope it does $SVA
👍️0
mick mick 2 years ago
$SVA News: COVID-19-Impfstoff von SINOVAC erhält in Brasilien Notfallzulassung für Kinder im Alter von 3 bis 5 Jahren 07/14/2022 01:36:00 PM
SVA News: Le vaccin SINOVAC contre le COVID-19 est autorisé pour une utilisation d’urgence chez les enfants âgés de 3 à 5 ans au Brésil 07/14/2022 01:00:00 PM
👍️0
mick mick 2 years ago
$SVA News: SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil 07/14/2022 11:02:00 AM
👍️0
mick mick 2 years ago
$SVA News: SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil 07/14/2022 05:10:00 AM
SVA News: SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa 06/25/2022 12:30:00 AM
👍️0

Your Recent History

Delayed Upgrade Clock